Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 6776 - 6800 of 8030 in total
Bindarit has been used in trials studying the prevention and treatment of Coronary Restenosis and Diabetic Nephropathy.
Investigational
Matched Description: … Bindarit has been used in trials studying the prevention and treatment of Coronary Restenosis and Diabetic …
Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).
Investigational
Matched Description: … Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and …
Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.
Investigational
Matched Description: … Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, …
Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac Vein Obstruction.
Investigational
Matched Description: … Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac …
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
Investigational
Matched Description: … Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of
Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).
Investigational
Matched Description: … Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid …
Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
Investigational
Matched Description: … Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed …
(S)-Propafenone is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone to Treat Atrial Fibrillation).
Investigational
Matched Description: … (S)-Propafenone is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone …
NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
Investigational
Matched Description: … NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder …
TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.
Investigational
Matched Description: … TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157] …
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
Investigational
Matched Description: … Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers …
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
Matched Description: … MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins. …
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
Matched Description: … BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis …
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Investigational
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).
Investigational
Matched Description: … RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase …
PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Investigational
Matched Description: … PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme …
CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal...
Investigational
Matched Description: … Studies attempting to understand the candidacidal activity of derivatives of alpha-MSH have focused on ... shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of ... The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial …
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Matched Description: … It appears to work in the area of the brain where new memories are formed. ... MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. …
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway …
Also known as protocatechuic aldehyde, protocatechualdehyde is a naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of the herb S. miltiorrhiza . Protocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes...
Experimental
Matched Description: … properties against human breast cancer cells and colorectal cancer cells by reducing the expression of ... naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Description: … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to ... Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation …
A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES. [PubChem]
Experimental
Matched Description: … It is a coenzyme of some DEHYDROGENASES. [PubChem] …
5'-Adenylic acid, monoanhydride with sulfuric acid. The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.
Experimental
Investigational
Matched Description: … The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. …
Allosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources, particularly from Candida albicans, and can be utilized as potent antifungal agent.
Experimental
Matched Description: … Allosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources …
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigational
Matched Description: … It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms …
Displaying drugs 6776 - 6800 of 8030 in total